MASCC Risk Index for Febrile Neutropenia
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- High Risk0–20
- Low Risk21–26
The MASCC Risk Index for Febrile Neutropenia calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include burden of illness. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.
Clinical Indication
The MASCC Risk Index for Febrile Neutropenia is indicated for bedside clinical practice to support Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Positive predictive value of 91% for low-risk classification in original validation.
MASCC Risk Index = Burden of illness points + Hypotension points + COPD points + Cancer type points + Dehydration points + Fever onset status points + Age points. Maximum score 26 points. Score ≥21 indicates low risk for complications.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| burden_of_illness | string | Yes | Burden of illness based on symptom severity assessment. Reflects overall clinical condition and symptom burden at presentation |
| hypotension | string | Yes | Presence of hypotension defined as systolic blood pressure <90 mmHg. Hypotension indicates hemodynamic instability and higher complication risk |
| active_copd | string | Yes | Active chronic obstructive pulmonary disease. COPD increases risk of respiratory complications during febrile neutropenia |
| cancer_type | string | Yes | Type of underlying cancer and history of fungal infection. Hematologic malignancies with prior fungal infection carry higher complication risk |
| dehydration_requiring_iv | string | Yes | Dehydration requiring intravenous fluid therapy. Indicates volume depletion and potential for hemodynamic compromise |
| fever_onset_status | string | Yes | Patient status at fever onset (outpatient vs inpatient). Outpatient onset typically associated with lower complication risk |
| patient_age | integer | Yes | Patient age in years. Age ≥60 years associated with increased complication risk in febrile neutropenia(years) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–20 | High Risk | High risk for complications |
| 21–26 | Low Risk | Low risk for complications |
Evidence-Based References (EBM)
- Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. doi: 10.1200/JCO.2000.18.16.3038.DOI: 10.1200/JCO.2000.18.16.3038
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.DOI: 10.1093/cid/cir073
- Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004 Aug;12(8):555-60. doi: 10.1007/s00520-004-0614-5.DOI: 10.1007/s00520-004-0614-5